Innogenetics NV
This article was originally published in The Gray Sheet
Executive Summary
Firm's North American subsidiary Innogenetics, Inc. acquires Avant Immunotherapeutics' TRAx diagnostic product line for an undisclosed amount in cash and royalty payments, the firms announce Aug. 25. The deal gives Innogenetics worldwide rights to "sell, market and manufacture" the diagnostics "as well as the patent and trademark portfolio." The TRAx CD4 enzyme-linked immunoassay was launched in the U.S. in 1995 following 510(k) clearance and is indicated to enumerate CD4 T cells via monoclonal antibodies to measure specific T lymphocytes in blood samples